<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02529579</url>
  </required_header>
  <id_info>
    <org_study_id>cellular immunotherapy</org_study_id>
    <nct_id>NCT02529579</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ImmunoGene Biotechology Co.,Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changhai Hospital</source>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and efficacy of iAPA-DC/CTL combined
      gemcitabine therapy on advanced pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-month SR</measure>
    <time_frame>6 months</time_frame>
    <description>6 months survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>6 months</time_frame>
    <description>progression-Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>6 months</time_frame>
    <description>Over survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>2 months</time_frame>
    <description>Objective Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QOL</measure>
    <time_frame>2 months</time_frame>
    <description>Quality of Life</description>
  </secondary_outcome>
  <other_outcome>
    <measure>immunological markers</measure>
    <time_frame>2 months</time_frame>
    <description>CD3, CD4,CD8,CD16,CD56,CD45,Treg(CD4,CD25, CD127low), IL-1B,IL-2R, IL-10,TNF-aï¼Œ</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum tumor biomarker</measure>
    <time_frame>2 months</time_frame>
    <description>CA19-9,CEA</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">187</enrollment>
  <condition>Carcinoma, Pancreatic Ductal</condition>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Gemcitabine Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cellular immunotherapy &amp; Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iAPA-DC/CTL adoptive cellular immunotherapy combined Standard Gemcitabine Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>iAPA-DC/CTL adoptive cellular immunotherapy</intervention_name>
    <description>twice DC cell infusion and CTL cell infusion for 6 times</description>
    <arm_group_label>cellular immunotherapy &amp; Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>standard Gemcitabine therapy</description>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_label>cellular immunotherapy &amp; Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced Pancreatic cancer patients with histological pathology confirmation

          2. Both gender, aged 18-70 year-old

          3. Bone marrow functioned well

          4. Renal function normal

          5. Liver function normal

          6. patients are voluntary, and willing to sign informed consent

          7. expected lifetime was at least 3 months

        Exclusion Criteria:

          1. With acute inflammation

          2. Accompanied with primary malignant tumor other than pancreas

          3. with autoimmune disease

          4. using corticosteroid or other suppress immune hormone treatment

          5. had transplant operation of vital organs

          6. active hepatitis

          7. HIV positive

          8. dysfunction in blood coagulation

          9. serious diseases in circulatory and respiratory systems

         10. pregnancy or breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaoshen Ii, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hosptial,Second Military medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhaoshen Li, MD</last_name>
    <phone>+86-21-25070552</phone>
    <email>zhaoshenlismmu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jun Gao, PhD</last_name>
    <phone>+86-13816012151</phone>
    <email>13816012151@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Changhai Hospital, Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhaoshen Li, MD</last_name>
      <phone>86-21-81873241</phone>
      <email>zhaoshenlismmu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>zhaoshen Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2015</study_first_posted>
  <last_update_submitted>August 19, 2015</last_update_submitted>
  <last_update_submitted_qc>August 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoshen Li</investigator_full_name>
    <investigator_title>director of department of gastroenterology</investigator_title>
  </responsible_party>
  <keyword>adoptive Cellular Immunotherapy</keyword>
  <keyword>patient safety</keyword>
  <keyword>therapeutic effect</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Pancreatic Ductal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

